CA3030841A1 - Multiple bi-specific binding domain constructs with different epitope binding to treat cancer - Google Patents

Multiple bi-specific binding domain constructs with different epitope binding to treat cancer Download PDF

Info

Publication number
CA3030841A1
CA3030841A1 CA3030841A CA3030841A CA3030841A1 CA 3030841 A1 CA3030841 A1 CA 3030841A1 CA 3030841 A CA3030841 A CA 3030841A CA 3030841 A CA3030841 A CA 3030841A CA 3030841 A1 CA3030841 A1 CA 3030841A1
Authority
CA
Canada
Prior art keywords
seq
group
bdc
cdr sequences
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3030841A
Other languages
English (en)
French (fr)
Inventor
Christopher Mehlin
Colin CORRENTI
James Olson
Roland B. WALTER
Ashok BANDARANAYAKE
George S. LASZLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CA3030841A1 publication Critical patent/CA3030841A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3030841A 2016-07-14 2017-07-14 Multiple bi-specific binding domain constructs with different epitope binding to treat cancer Abandoned CA3030841A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662362397P 2016-07-14 2016-07-14
US62/362,397 2016-07-14
US201762480230P 2017-03-31 2017-03-31
US62/480,230 2017-03-31
PCT/US2017/042264 WO2018014001A1 (en) 2016-07-14 2017-07-14 Multiple bi-specific binding domain constructs with different epitope binding to treat cancer

Publications (1)

Publication Number Publication Date
CA3030841A1 true CA3030841A1 (en) 2018-01-18

Family

ID=60952209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030841A Abandoned CA3030841A1 (en) 2016-07-14 2017-07-14 Multiple bi-specific binding domain constructs with different epitope binding to treat cancer

Country Status (6)

Country Link
US (1) US20190233534A1 (https=)
EP (1) EP3484516A4 (https=)
JP (1) JP2019532017A (https=)
AU (1) AU2017297603A1 (https=)
CA (1) CA3030841A1 (https=)
WO (1) WO2018014001A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12116406B2 (en) 2017-05-26 2024-10-15 Fred Hutchinson Cancer Center Anti-CD33 antibodies and uses thereof
WO2019246514A1 (en) * 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
CN109485734B (zh) * 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
PH12021500041A1 (en) * 2019-04-09 2022-06-06 Sanofi Sa Trispecific binding proteins, methods, and uses thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
CA3142838A1 (en) * 2019-06-27 2020-12-30 Verseau Therapeutics, Inc. Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
WO2021202793A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Chimeric antigen receptors targeting cd33
CA3173205A1 (en) * 2020-03-31 2021-10-07 Roland B. WALTER Human anti-cd33 antibodies and uses thereof
WO2021202799A2 (en) 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Chimeric antigen receptors targeting cd33
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022094299A2 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
MX2023009022A (es) * 2021-02-02 2023-10-23 Numab Therapeutics AG Anticuerpos multiespecificos con especificidad para ror1 y cd3.
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
WO2026069278A1 (en) * 2024-09-30 2026-04-02 Orum Therapeutics, Inc. Anti-cd123 antibodies and neodegrader conjugates

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU3998800A (en) 1999-02-12 2000-08-29 Genetics Institute, Llc Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
ES2393485T3 (es) 2003-07-02 2012-12-21 Innate Pharma Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2008103849A2 (en) 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
KR20090088891A (ko) 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP5841332B2 (ja) 2008-07-18 2016-01-13 国立大学法人名古屋大学 細胞増殖阻害剤
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
WO2010124188A1 (en) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
US20110165161A1 (en) * 2009-12-23 2011-07-07 Shih-Yao Lin Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
NZ609201A (en) * 2010-10-27 2015-01-30 Amgen Res Munich Gmbh Means and methods for treating dlbcl
US9758586B2 (en) * 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2881981A1 (en) * 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
CN110894240B (zh) * 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体

Also Published As

Publication number Publication date
EP3484516A4 (en) 2020-03-18
EP3484516A1 (en) 2019-05-22
AU2017297603A1 (en) 2019-02-14
WO2018014001A1 (en) 2018-01-18
US20190233534A1 (en) 2019-08-01
JP2019532017A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
US20190233534A1 (en) Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2021286676B2 (en) Engineered immune cell expressing NK inhibitory molecule and use thereof
EP3240805B1 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
KR20220169488A (ko) 신규한 항원 결합 도메인 및 이를 포함하는 합성 항원 수용체
EP4219693A1 (en) Chimeric antigen receptor targeting cd7 and use thereof
JP7649239B2 (ja) キメラ抗原受容体ファクトリおよびその使用方法
AU2019301070A1 (en) Fusion constructs and methods of using thereof
JP2021534762A (ja) 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用
JP2019518424A (ja) 選択的タンパク質発現のための組成物および方法
TW202342734A (zh) 具有抗-cd19/抗-cd22嵌合抗原受體之基因工程細胞及其用途
IL297916A (en) Compositions and methods for tcr reprogramming using CD70-specific fusion proteins
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
AU2021305234A1 (en) Fusion constructs and methods of using thereof
EP4491636A1 (en) Antibody or antigen-binding fragment thereof that targets cotinine, chimeric antigen receptor comprising same, and uses thereof
WO2025059589A1 (en) Immune cell engaging molecules
US20230212286A1 (en) Antibodies specific for cd22 and uses thereof
WO2024140710A1 (zh) 一种特异性结合lilrb4的合成t细胞受体抗原受体及其应用
WO2023246574A1 (zh) 靶向gpc3的抗体及其用途
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
HK40077828A (en) Engineered immune cell expressing nk inhibitory molecule and use thereof
WO2020150513A1 (en) Methods to enhance the selectivity and effectiveness of cancer treatments
WO2026022767A1 (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231011